Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Acusphere, Inc.

Market Cap 3.46M 3.02M 2.8M 2.62M 4.91M 327M 4.94M 33.19M 12.86M 161M 13.01M 12.73M 559M P/E 2006
-1.06x
P/E 2007 -0.49x
Enterprise Value -11.29M -9.85M -9.12M -8.54M -16.01M -1.07B -16.11M -108M -41.93M -524M -42.39M -41.48M -1.82B EV / Sales 2006
9,811,030x
EV / Sales 2007 5,744,305x
Free-Float
100%
Yield 2006 *
-
Yield 2007 -
Change 5-day change 1-year change 3-year change Capi.($)
+0.74%+1.69%+10.40%+85.32% 46.74B
-2.91%+3.09%+50.06%+90.35% 34.33B
-0.27%-2.71%-9.86%+33.69% 11.57B
-0.34%-3.07%+11.88%+92.57% 11.42B
-0.57%+0.96%+37.43%+128.26% 9.09B
+0.43%-1.68%+13.22%+41.07% 6.98B
+2.77%+1.83%+35.25%+243.81% 6.62B
-1.23%+1.65%+44.63%-18.54% 6.55B
+0.73%-2.94%-35.25%-2.32% 5B
Average -0.07%+0.08%+17.53%+77.13% 15.37B
Weighted average by Cap. -0.44%+0.99%+21.75%+82.93%

Financials

2006 2007
Net sales 1.78 1.55 1.44 1.35 2.52 168.05 2.54 17.06 6.61 82.72 6.69 6.54 287.22 2.67 2.33 2.15 2.02 3.78 251.65 3.8 25.55 9.9 123.87 10.01 9.8 430.1
Net income -61.09M -53.26M -49.33M -46.18M -86.61M -5.76B -87.13M -585M -227M -2.84B -229M -224M -9.85B -53.73M -46.85M -43.39M -40.62M -76.17M -5.07B -76.64M -515M -199M -2.5B -202M -197M -8.66B
Net Debt -52.87M -46.1M -42.7M -39.97M -74.96M -4.99B -75.41M -507M -196M -2.46B -198M -194M -8.53B -14.76M -12.87M -11.92M -11.16M -20.92M -1.39B -21.05M -141M -54.79M -685M -55.4M -54.21M -2.38B
Logo Acusphere, Inc.
Acusphere, Inc. is a specialty pharmaceutical company. The Company is focused on the development of Imagify, which contains Perflubutane Polymer Microspheres for injectable suspension. The Company's product Imagify is a cardiovascular drug for the detection of coronary artery disease (CAD). Imagify injectable suspension consists of porous, synthetic polymer microspheres containing gas that are administered intravenously and act as tracers of blood flow or perfusion. The Company has submitted the Marketing Authorization Application (MAA) for its lead product candidate, Imagify lyophilisate for dispersion for injection with the European Medicines Agency (EMA) to support the regulatory review of Imagify in the European Union (EU).
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!